Gentile Kimberly 4

Accession 0001562180-22-007085

CIK 0001935979other

View on SEC.gov Company Profile

Filed

Oct 4, 8:00 PM ET

Accepted

Oct 5, 5:42 PM ET

Size

86.1 KB

Accession

0001562180-22-007085

Insider Transaction Report

Form 4

Period: 2022-10-03

Biohaven Ltd.BHVN

Gentile Kimberly

SVP, Clinical Operations

Transactions

Other
Common Shares
2022-10-03+6,500→ 12,326 total
Exercise/Conversion
Common Shares
2022-10-03$6.37/sh+387$2,465→ 18,338 total
Exercise/Conversion
Common Shares
2022-10-03$6.37/sh+12,612$80,338→ 30,950 total
Exercise/Conversion
Common Shares
2022-10-03$4.13/sh+1,199$4,952→ 32,149 total
Exercise/Conversion
Common Shares
2022-10-03$4.13/sh+13,801$56,998→ 45,950 total
Exercise/Conversion
Common Shares
2022-10-03$1.61/sh+1,542$2,483→ 95,450 total
Exercise/Conversion
Common Shares
2022-10-03$1.03/sh+295$304→ 95,745 total
Other
Stock Options (Right to Buy)
2022-10-03+12,500→ 12,500 total
Exercise: $0.54Exp: 2027-04-05→ Common Shares (12,500 underlying)
Exercise/Conversion
Stock Options (Right to Buy)
2022-10-03−12,612→ 0 total
Exercise: $6.37Exp: 2032-01-07→ Common Shares (12,612 underlying)
Exercise/Conversion
Stock Options (Right to Buy)
2022-10-03−13,801→ 0 total
Exercise: $4.13Exp: 2031-01-06→ Common Shares (13,801 underlying)
Exercise/Conversion
Stock Options (Right to Buy)
2022-10-03−30,958→ 0 total
Exercise: $1.61Exp: 2028-11-20→ Common Shares (30,958 underlying)
Exercise/Conversion
Stock Options (Right to Buy)
2022-10-03−1,542→ 0 total
Exercise: $1.61Exp: 2028-11-20→ Common Shares (1,542 underlying)
Exercise/Conversion
Stock Options (Right to Buy)
2022-10-03−20,716→ 0 total
Exercise: $1.03Exp: 2027-12-06→ Common Shares (20,716 underlying)
Exercise/Conversion
Stock Options (Right to buy)
2022-10-03−4,500→ 0 total
Exercise: $1.86Exp: 2027-09-04→ Common Shares (4,500 underlying)
Other
Stock Options (Right to Buy)
2022-10-03+1,199→ 1,199 total
Exercise: $4.13Exp: 2031-01-06→ Common Shares (1,199 underlying)
Other
Stock Options (Right to Buy)
2022-10-03+3,000→ 3,000 total
Exercise: $2.52Exp: 2029-03-22→ Common Shares (3,000 underlying)
Other
Stock Options (Right to Buy)
2022-10-03+1,542→ 1,542 total
Exercise: $1.61Exp: 2028-11-20→ Common Shares (1,542 underlying)
Other
Stock Options (Right to Buy)
2022-10-03+295→ 295 total
Exercise: $1.03Exp: 2027-12-06→ Common Shares (295 underlying)
Other
Stock Options (Right to Buy)
2022-10-03+20,716→ 20,716 total
Exercise: $1.03Exp: 2027-12-06→ Common Shares (20,716 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2022-10-03−12,500→ 0 total
Exercise: $0.54Exp: 2027-04-05→ Common Shares (12,500 underlying)
Exercise/Conversion
Common Shares
2022-10-03$1.03/sh+20,716$21,337→ 116,461 total
Exercise/Conversion
Common Shares
2022-10-03$1.86/sh+4,500$8,370→ 120,961 total
Exercise/Conversion
Common Shares
2022-10-03$0.54/sh+12,500$6,750→ 133,461 total
Tax Payment
Common Shares
2022-10-03$7.00/sh−37,492$262,444→ 95,969 total
Other
Stock Options (Right to Buy)
2022-10-03+387→ 387 total
Exercise: $6.37Exp: 2032-01-07→ Common Shares (387 underlying)
Other
Stock Options (Right to Buy)
2022-10-03+12,612→ 12,612 total
Exercise: $6.37Exp: 2032-01-07→ Common Shares (12,612 underlying)
Other
Stock Options (Right to Buy)
2022-10-03+13,801→ 13,801 total
Exercise: $4.13Exp: 2031-01-06→ Common Shares (13,801 underlying)
Other
Stock Options (Right to Buy)
2022-10-03+14,000→ 14,000 total
Exercise: $2.84Exp: 2029-11-25→ Common Shares (14,000 underlying)
Other
Stock Options (Right to Buy)
2022-10-03+30,958→ 30,958 total
Exercise: $1.61Exp: 2028-11-20→ Common Shares (30,958 underlying)
Other
Stock Options (Right to Buy)
2022-10-03+4,500→ 4,500 total
Exercise: $1.86Exp: 2027-09-04→ Common Shares (4,500 underlying)
Exercise/Conversion
Stock Options (Right to Buy)
2022-10-03−387→ 0 total
Exercise: $6.37Exp: 2032-01-07→ Common Shares (387 underlying)
Exercise/Conversion
Stock Options (Right to Buy)
2022-10-03−3,000→ 0 total
Exercise: $2.52Exp: 2029-03-22→ Common Shares (3,000 underlying)
Exercise/Conversion
Stock Options (Right to Buy)
2022-10-03−295→ 0 total
Exercise: $1.03Exp: 2027-12-06→ Common Shares (295 underlying)
Other
Common Shares
2022-10-03+5,826→ 5,826 total
Other
Common Shares
2022-10-03+1,875→ 17,951 total
Exercise/Conversion
Stock Options (Right to Buy)
2022-10-03−1,199→ 0 total
Exercise: $4.13Exp: 2031-01-06→ Common Shares (1,199 underlying)
Exercise/Conversion
Stock Options (Right to Buy)
2022-10-03−14,000→ 0 total
Exercise: $2.84Exp: 2029-11-25→ Common Shares (14,000 underlying)
Award
Stock Options (Right to buy)
2022-10-03+300,000→ 300,000 total
Exercise: $7.00Exp: 2032-10-04→ Common Shares (300,000 underlying)
Other
Common Shares
2022-10-03+3,750→ 16,076 total
Exercise/Conversion
Common Shares
2022-10-03$2.84/sh+14,000$39,760→ 59,950 total
Exercise/Conversion
Common Shares
2022-10-03$2.52/sh+3,000$7,560→ 62,950 total
Exercise/Conversion
Common Shares
2022-10-03$1.61/sh+30,958$49,842→ 93,908 total

Footnotes (5)

[F1]Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer").
[F2]Effective as of the Distribution, each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement.
[F3]These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options.
[F4]Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.
[F5]The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Documents

1 file

4
primarydocument.xmlPrimary
PRIMARY DOCUMENT

Issuer

Biohaven Ltd.

CIK 0001935979

→

Entity typeother

Related Parties

filerCIK 0001704186

Filing Metadata

Form type: 4
Filed: Oct 4, 8:00 PM ET
Accepted: Oct 5, 5:42 PM ET
Size: 86.1 KB

View on SEC.gov